ROCKET PHARMACEUTICALS (RCKT) stock: insider trades, news & valuation
Net sellingShare price and insider trades
ROCKET PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $34K and 6 sold $979K of RCKT stock on the open market.
Get emailed when insiders cluster-buy stocks like RCKT
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
RCKT insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $432K | 7 |
| Q2 2026 | — | 0 | $275K | 8 |
| Q1 2026 | $34K | 1 | $122K | 6 |
| Q4 2025 | — | 0 | $149K | 8 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 ROCKET PHARMACEUTICALS, INC. insider reported open-market purchases totaling $34K, while 6 insiders reported sales totaling $979K. 0 of 29 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 15SEC | Martin WilsonGeneral Counsel | Sell | 75,364598,489 held (−11%) | $3.40 | $256K | -24.7% | — |
| Aug 20SEC | Gaurav ShahCEO | Sell | 2,2931,056,594 held (−0%) | $3.38 | $8K | -24.3% | — |
| Aug 20SEC | Martin WilsonGeneral Counsel | Sell | 631673,853 held (−0%) | $3.38 | $2K | -24.3% | — |
| Aug 17SEC | Martin WilsonGeneral Counsel | Sell | 3,493674,484 held (−1%) | $3.38 | $12K | -24.3% | — |
| Aug 17SEC | Gaurav ShahCEO | Sell | 2,8371,058,887 held (−0%) | $3.38 | $10K | -24.3% | — |
| Aug 13SEC | Christopher James StevensCOO | Sell | 36,658505,784 held (−7%) | $3.50 | $128K | -26.9% | — |
| Aug 13SEC | Sarbani ChaudhuriSee Remarks | Sell | 4,701262,809 held (−2%) | $3.50 | $16K | -26.9% | — |
| May 26SEC | Gaurav ShahCEO | Sell | 55,6841,061,724 held (−5%) | $3.09 | $172K | -17.2% | — |
| May 21SEC | Gaurav ShahCEO | Sell | 2,4091,040,918 held (−0%) | $3.01 | $7K | -15.0% | — |
| May 21SEC | Martin WilsonGeneral Counsel | Sell | 662677,977 held (−0%) | $3.01 | $2K | -15.0% | — |
| May 21SEC | John MilitelloSee Remarks | Sell | 38489,780 held (−0%) | $3.01 | $1K | -15.0% | — |
| May 14SEC | Martin WilsonGeneral Counsel | Sell | 3,361678,639 held (−0%) | $3.61 | $12K | -29.1% | — |
| May 14SEC | Gaurav ShahCEO | Sell | 2,7281,043,327 held (−0%) | $3.61 | $10K | -29.1% | — |
| May 14SEC | John MilitelloSee Remarks | Sell | 85590,164 held (−1%) | $3.61 | $3K | -29.1% | — |
| May 11SEC | Sarbani ChaudhuriSee Remarks | Sell | 17,650267,510 held (−6%) | $3.84 | $68K | -33.3% | — |
| Feb 20SEC | Gaurav ShahCEO | Sell | 5,9901,046,055 held (−1%) | $3.34 | $20K | -23.4% | — |
| Feb 20SEC | Martin WilsonGeneral Counsel | Sell | 1,376682,000 held (−0%) | $3.34 | $5K | -23.4% | — |
| Feb 20SEC | John MilitelloSee Remarks | Sell | 1,15791,019 held (−1%) | $3.34 | $4K | -23.4% | — |
| Feb 18SEC | Gaurav ShahCEO | Sell | 12,2791,052,045 held (−1%) | $3.31 | $41K | -22.7% | — |
| Feb 18SEC | Martin WilsonGeneral Counsel | Sell | 12,253683,376 held (−2%) | $3.31 | $41K | -22.7% | — |
| Feb 18SEC | John MilitelloSee Remarks | Sell | 3,72692,176 held (−4%) | $3.31 | $12K | -22.7% | — |
| Jan 6SEC | Elisabeth BjorkDirector | Buy | 10,00050,000 held (+25%) | $3.44 | $34K | -25.6% | — |
| Nov 20SEC | Gaurav ShahCEO | Sell | 6,276778,296 held (−1%) | $2.98 | $19K | -14.1% | — |
| Nov 20SEC | Jonathan David SchwartzSee Remarks | Sell | 2,545299,064 held (−1%) | $2.98 | $8K | -14.1% | — |
| Nov 20SEC | Martin WilsonGeneral Counsel | Sell | 1,646383,816 held (−0%) | $2.98 | $5K | -14.1% | — |
| Nov 20SEC | John MilitelloSee Remarks | Sell | 1,08665,920 held (−2%) | $2.98 | $3K | -14.1% | — |
| Oct 16SEC | John MilitelloSee Remarks | Sell | 19,84176,083 held (−21%) | $3.96 | $79K | -35.4% | — |
| Oct 16SEC | John MilitelloSee Remarks | Sell | 5,51470,569 held (−7%) | $3.97 | $22K | -35.5% | — |
| Oct 16SEC | John MilitelloSee Remarks | Sell | 3,00567,564 held (−4%) | $3.97 | $12K | -35.5% | — |
| Oct 16SEC | John MilitelloSee Remarks | Sell | 55867,006 held (−1%) | $3.98 | $2K | -35.7% | — |
Insiders at ROCKET PHARMACEUTICALS, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Martin WilsonGeneral Counsel | — | $334K | Sep 15, 2026 | — |
| Gaurav ShahCEO | — | $286K | Aug 20, 2026 | — |
| John MilitelloSee Remarks | — | $138K | May 21, 2026 | — |
| Christopher James StevensCOO | — | $128K | Aug 13, 2026 | — |
| Elisabeth BjorkDirector | $34K | — | Jan 6, 2026 | — |
| Sarbani ChaudhuriSee Remarks | — | $84K | Aug 13, 2026 | — |
| Jonathan David SchwartzSee Remarks | — | $8K | Nov 20, 2025 | — |
RCKT stock: common questions
Are ROCKET PHARMACEUTICALS, INC. insiders buying RCKT stock?
In the past 12 months, 1 insiders reported open-market purchases of RCKT worth $34K. The latest was Director Elisabeth Bjork bought $34K of RCKT at $3.44 — first open-market purchase in our records; raises the stake by 25%.
Are ROCKET PHARMACEUTICALS, INC. insiders selling RCKT stock?
6 insiders reported sales worth $979K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is RCKT's 52-week range?
Over the past year RCKT has traded between $2.48 and $5.30. It last closed at $2.56 on Oct 9, 2026.